|
Neurophysiology
Research Lab
Ischemia Studies, Retinal Physiology, Human Cerebral
Vasculature, and Collaborative Projects
Ischemia Studies
(a) Middle cerebral artery occlusion (MCAO)
stroke (ischemia) model in the rabbit. This model is being used by
Dr. Ogilvy to test purified, polymerized hemoglobin from Biopure as
a means of achieving neuroprotection by reducing infarct volume. Recently
acquired data will be presented at the upcoming annual Society for
Neuroscience meeting in November (Soc Neurosci. Abstr. 20, p.180).
(b) The model will also be used to
test the strategy that reducing energy requirements of neuronal
tissue may be neuroprotective during periods of poor energy supply,
e.g. during planned ischemia in some neurosurgical procedures (e.g.
clipping aneurysms, arteriovenous malformations), and following
ischemic episodes (e.g. stroke).
(c) In order to test this hypothesis,
Dr. Ames has developed a "cocktail" of agents which temporarily
block energy demanding metabolic processes. In a manuscript recently
submitted to the Journal of Cerebral Blood Flow and Metabolism,
Drs. Ames and Maynard showed that this "cocktail" was
able to functionally (light-evoked compound action potentials from
the optic nerve were recorded) protect the in vitro rabbit retina
preparation, developed by Dr. Ames, during periods of 3 h of ischemia.
Future efforts involve refinement
of the cocktail to include more clinically useful agents, i.e. agents
which cross the blood brain barrier, yet have the same effect in
both the in vitro and in vivo preparations. Cardiovascular toxicity
of such a cocktail is also to be tested in vivo in rats and rabbits.
(d) Drs. Ogilvy and Maynard have recently
started a multidepartmental study to develop a baboon model of focal
ischemia. Using intra-arterial balloon occlusion of the middle cerebral
artery for 3 h, followed by 1 h of reperfusion, this model will
combine and compare functional CT scanning to measure the cerebral
volume at risk from the 3 h MCAO, and diffusion weighted imaging
MRI measurement of the actual infarct volume in the baboon brain
ex vivo. Traditional histological staining of the cerebral infarct
will also be assessed for microscopic analysis. A recently developed
anti-selectin monoclonal antiserum (Boehringer Ingelheim) will be
used to assess its potential as a neuroprotective agent in these
on-going pilot experiments.
Retinal Physiology
Using the in vitro rabbit retina preparation
previously mentioned, Drs. Maynard, Ames and Ogilvy are also examining
the involvement of nitric oxide (NO) in retinal (neuronal) function
and in ischemia. Staining for both the enzyme required for synthesis
of the putative neurotransmitter, NO synthase, and a crucial cofactor,
B-Nicotinamide adenine dinucleotide phosphate (NADPH) have been
localised in the mammalian retina. In addition, a variety of single
cell physiological recording experiments have implicated the involvement
of NO in retinal neurotransmission. The preparation used in our
laboratory, developed by Dr. Ames, is to our knowledge based on
literature searches, the only existing preparation from which both
the electroretinogram and compound action potentials from the optic
nerve of an intact mammalian retina are physiologically recorded
simultaneously. Our initial results were communicated at a satellite
symposium on "Nitric oxide in the nervous system", July
1994, Montreal (Neuropharmacology, In Press), and more recent data
will be presented at the upcoming annual Society for Neuroscience
conference (Soc. Neurosci. Abstr. 20, p.218). A full manuscript
has been submitted for publication in Investigative Ophthalmology
and Visual Science. These experiments will proceed to examine the
physiological consequences of manipulating the activity of NO synthase
during ischemia, since the literature to date is unclear as to whether
increases or decreases in NO are neuroprotective during stroke.
Human Cerebral Vasculature
Although much is known about the types
of perivascular nerves and their origin in the cerebrovasculature
through immunohistochemical studies on animals, very little has
been reported on human cerebral vessels. Drs. Maynard and Ogilvy
have therefore begun investigations to try to characterise the innvervation
of the human cerebrovasculature, and to examine the innervation
in abnormal cerebral vessels excised during surgical procedures.
Recent findings were communicated at the American Heart Association
Stroke conference in February 1994 (Stroke 25, 268) and a full paper
is accepted for publication in Journal of Neurosurgery. This report
identifies the presence and density of innvervation of calcitonin
gene-related peptide (sensory), vasoactive intestinal polypeptide
(parasympathetic) and neuropeptide Y (sympathetic) in major human
cerebral and cerebellar arteries, and their absence in arteriovenous
malformations. Future studies will include confirming the assumed
characterisation (based on animal studies these peptide are characterised
according to the nerve-types in parentheses above), using chemical
denervation techniques. In addition, other abnormal vessels excised
from surgery will continue to be assessed for the presence/absence
of innervation, which may provide some insight as to the control
of blood flow in these pathological cases.
Collaborative Projects
Dr. C. S. Ogilvy has a number of clinical
research projects ongoing with other members of the Neurosurgical
Service. Dr. K. I. Maynard also has ongoing collaborations with
Dr. Michael A. Moskowitz of the Neurology Service related to migraine
research (see Rebeck, Maynard, Hyman and Moskowitz, 1994, Proc Natl.
Acad. Sci. 91, 3666-3669), and also in association with Drs. M.
Fisher and P. Huang, investigations examining possible compensatory
mechanisms of the cerebrovascular innervation in NO synthase (gene)
knock-out mice.
|
|
Neurosurgery
Clinical Units
|
|
|